HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients
HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC
PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma
Can multiple endpoints in MM clinical papers create new insights?
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor
Highlights from ASCO 2021
OncoAlert and ecancer ASCO roundup - Day 3
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC
OncoAlert and ecancer ASCO roundup - Day 2
OncoAlert and ecancer ASCO roundup - Day 1
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC